Equity Overview
Price & Market Data
Price: $8.35
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $90,410,464
Daily Volume: 0
Performance Metrics
1 Week: 5.83%
1 Month: 68.69%
3 Months: 87.64%
6 Months: -0.36%
1 Year: -18.88%
YTD: 12.38%
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.